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a measure of hypoperfusion. WML severity was associ-
ated with both axonal loss and demyelination in AD, but 
only with demyelination in controls. Calpain was signifi-
cantly increased in WML tissue in AD, whereas MAG:PLP 
was significantly reduced in controls. Calpain levels were 
associated with increasing amounts of cortical AD-pathol-
ogy but not SVD. We conclude that parietal WML seen 
in AD differ in their pathological composition and aetiol-
ogy compared to WML seen in aged controls: WML seen 
in AD may be associated with Wallerian degeneration that 
is triggered by cortical AD-pathology, whereas WML in 
aged controls are due to ischaemia. Hence, parietal WML 
as seen on MRI should not invariably be interpreted as a 
surrogate biomarker for SVD as they may be indicative 
of cortical AD-pathology, and therefore, AD should also 
be considered as the main underlying cause for cognitive 
impairment in cases with parietal WML.
Keywords White matter lesion · White matter 
hyperintensity · Alzheimer’s disease · Small vessel disease · 
Hyperphosphorylated tau · Wallerian degeneration
Introduction
Cerebral white matter lesions (WML) are a frequent find-
ing at post-mortem histological examination of brains from 
both demented and non-demented elderly. They primarily 
encompass loss of integrity of the cerebral white matter due 
to rarefaction, which morphologically appear as demyelina-
tion when visualized with  histochemical myelin stains and 
may be due to loss of the axonal myelin sheath or axonal 
loss [25]. WML appear as white matter hyperintensities 
(WMH) on pre- and post-mortem T2-weighted magnetic 
resonance imaging (MRI) [27], and as altered diffusivity on 
Abstract Cerebral white matter lesions (WML) encom-
pass axonal loss and demyelination, and the pathogenesis is 
assumed to be small vessel disease (SVD)-related ischemia. 
However, WML may also result from the activation of Wal-
lerian degeneration as a consequence of cortical Alzhei-
mer’s disease (AD) pathology, i.e. hyperphosphorylated tau 
(HPτ) and amyloid-beta (Aβ) deposition. WML seen in AD 
have a posterior predominance compared to non-demented 
individuals but it is unclear whether the pathological and 
molecular signatures of WML differ between these two 
groups. We investigated differences in the composition and 
aetiology of parietal WML from AD and non-demented 
controls. Parietal WML tissue from 55 human post-mor-
tem brains (AD, n = 27; non-demented controls, n = 28) 
were quantitatively assessed for axonal loss and demyelina-
tion, as well as for cortical HPτ and Aβ burden and SVD. 
Biochemical assessment included Wallerian degeneration 
protease calpain and the myelin-associated glycoprotein 
(MAG) to proteolipid protein (PLP) ratio (MAG:PLP) as 
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diffusion tensor imaging (DTI) [7]. The burden of WMH 
increases with age [50] and is associated with cognitive 
decline and risk of dementia [14]. In Alzheimer’s disease 
(AD) patients WMH are found in up to 89% of cases [5] 
and are more severe than WMH seen in the non-demented 
elderly [40, 67].
WML/WMH are usually assumed to represent ischemia-
associated demyelination and axonal loss due to arterio-
pathy of the white matter arteries and arterioles, i.e. small 
vessel disease (SVD) [47]. Therefore, the detection of 
in vivo WMH often supports the diagnosis of cerebrovascu-
lar disease and, in patients with cognitive impairment, the 
diagnosis of vascular cognitive impairment/dementia (VCI/
VaD) over other forms of dementia such as AD [41]. How-
ever, previous neuroimaging [34, 51] and neuropathologi-
cal studies [40] suggest a multifactorial aetiology of WMH, 
in addition to SVD it may also include degenerative axonal 
loss secondary to the deposition of cortical AD pathol-
ogy, i.e. hyperphosphorylated tau (HPτ) and amyloid-beta 
(Aβ). Here, axonal loss in white matter could either occur 
as a consequence of cortical neuronal loss (later stages 
of AD), or as a result of retrograde Wallerian degenera-
tion, i.e. rapid irreversible fragmentation and destruction 
of the distal axon [38]. One of the main triggers of Wal-
lerian degeneration in AD is the disruption and/or block-
age of anterograde fast axonal transport [55]. Eventually 
impaired axonal transport leads to axonal dysregulation and 
increased intracellular calcium concentration activating the 
calcium-dependent cysteine protease calpain that mediates 
cytoskeletal breakdown, demyelination and axonal frag-
mentation [12, 13, 39].
In-vivo DTI studies support the concept of AD-asso-
ciated axonal changes as they have demonstrated specific 
topographical white matter changes, i.e. reduced axonal 
integrity, axonal swelling and demyelination that occur 
exclusively in AD patients. These changes include reduced 
integrity in white matter tracts connected to the medial tem-
poral lobe (MTL) [2, 31], the cingulum and in the tracts of 
the temporo-parietal regions such as the superior longitudi-
nal fasciculus [1, 7]. These changes in white matter struc-
ture have been directly associated with Wallerian degenera-
tion independent of cortical atrophy [3, 7, 28]. Moreover, 
AD cases with severe cortical AD pathology and severe 
WML exhibited only minimal SVD pathology at post-mor-
tem examination [17, 40], indicating that SVD was not the 
primary cause of WML in these cases.
In addition, cerebral amyloid angiopathy (CAA), a sub-
type of SVD characterized by the accumulation of Aβ in 
leptomeningeal, cortical and capillary vessel walls is 
seen in 80–100% of AD cases [4] was suggested to cause 
ischemia of the white matter as the presence of CAA has 
been shown to be associated with increased demyelina-
tion [59] and AD patients with CAA had higher burdens of 
WMH compared to AD patients without CAA [26]. How-
ever, others found no relationship between WMH and CAA 
[56] and the relationship between CAA and the pathogen-
esis of WML has not yet been clarified.
The underlying aetiology of WML is not restricted to 
SVD and may indeed be indicative of AD pathology. How-
ever, it is not clear whether WML associated with corti-
cal AD pathology differ in their pathological and molecu-
lar signatures from WML that are associated with SVD 
and such data are needed to further our understanding of the 
pathogenesis of WML. This is crucial as the current clini-
cal criteria for VaD/VCI [22] and mixed AD/VaD [16] are 
based on the detection of WMH, which are invariably inter-
preted as a surrogate marker of SVD resulting in misdiag-
nosis with a detrimental impact on the choice of therapeu-
tic interventions. Therefore, we investigated post-mortem 
brain tissue of AD and aged controls to identify differences 
in the composition and aetiology of WML in the parietal 
lobe using pathological and biochemical methods.
Methods
Study cohort
Our study cohort consisted of 55 human post-mortem 
brains (mean age 84.02 ± 7.94 years; male: 24, female: 
31). During life, all dementia subjects underwent clini-
cal assessments by board certified Old Age Psychiatrists 
or Neurologists and most were assessed in prospec-
tive research studies with repeated cognitive evaluation 
including the Mental State Examination (MMSE) [19] 
(MMSE scores were available for 18 out of 27 AD cases 
and for 6 out of 28 controls). All cases had a clinical 
review of records after death (AJT) at Newcastle Brain 
Tissue Resource (NBTR) and control subjects showed no 
evidence of cognitive impairment and had normal every-
day functioning up until death. AD cases were confirmed 
as having a clinical dementia due to AD. Brain tissue 
was obtained at autopsy and stored within the NBTR in 
accordance with Newcastle University Ethics Board 
(The Joint Ethics Committee of Newcastle and North 
Tyneside Health Authority, reference: 08/H0906/136). 
After autopsy the left hemisphere, brainstem and cer-
ebellum were dissected in coronal planes approximately 
0.7 cm intervals and snap frozen between copper plates 
at −120 °C and stored at −80 °C. The right hemisphere, 
brainstem and cerebellum were immersion fixed in 10% 
buffered aqueous formaldehyde solution for 6 weeks and 
then subsequently dissected in coronal planes approxi-
mately 0.7 cm intervals and paraffin-embedded. All brains 
underwent neuropathological assessment according to 
the National Institute on Aging-Alzheimer’s Association 
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(NIA-AA) criteria [44] that included assessment of Thal 
phases of Aβ deposition [57], Braak staging of neurofi-
brillary pathology [10] and Consortium to Establish a 
Registry for Alzheimer’s Disease (CERAD) scoring [43]. 
Additional neuropathological scoring of Lewy body 
pathology [9, 42], vascular pathology contribution to 
cognitive impairment (vascular impairment neuropatho-
logical guidelines (VCING)) [53], TDP-43 inclusions [30] 
and CAA [46] was performed. Cases did not contain any 
infarcts or cerebral haemorrhages. The final clinico-path-
ological diagnosis was AD in 27 cases, while no cognitive 
impairment and only mild age-associated neuropathologi-
cal changes were seen in 28 cases (controls) (Table 1).
Histological procedures
Paraffin-embedded serial sections from parietal blocks 
(Brodmann area 40/22) were cut at 6 μm thickness and 
mounted onto superfrost plus charged glass slides (Thermo 
Shandon, Cheshire, UK). The parietal lobe was selected 
as AD patients frequently show WMH in the posterior 
region inclusive of the parietal white matter [67] and this 
region contains large amounts of white matter for patho-
logical assessment. Sections underwent histological stain-
ing with Bielschowsky silver stain (cold method) [37] for 
assessment of axonal density, myelin stain luxol fast blue 
(LFB) to assess WML area and myelin pallor (as a measure 
Table 1  Demographic and neuropathological characteristics of study cohort
AD Alzheimer’s disease, df degrees of freedom; t Independent samples test, X2 Chi -squared test, F female, M Male, U Mann–Whitney U test, 
PMD post mortem delay, Aβ amyloid-beta, NFT neurofibrillary tangle, CERAD Consortium to Establish a Registry for Alzheimer’s Disease, 
NIA-AA National Institute on Ageing-Alzheimer’s Association criteria for AD neuropathologic change, LB Lewy body, VCING vascular cogni-
tive impairment neuropathological guidelines, CAA cerebral amyloid angiopathy, CapCAA capillary CAA, MMSE mini mental state examination
AD Control Statistic(df), p value
Cohort number 27 28
Mean age, years (±SD) 84.01 (6.84) 84.04 (9.00) t(53) = 0.17, p = 0.987
Gender M:F 11:16 13:15 χ2(1) = 0.181, p = 0.671
Mean PMD, hours (±SD) 51.53 (23.70) 53.00 (24.84) t(31) = 1.73, p = 0.864
Thal Aβ phase [57] Phase 4, n = 2
Phase 5, n = 25
Phase 0, n = 8 Phase 1, n = 9 Phase 2, n = 5 Phase 3, 
n = 3
Phase 4, n = 2
Phase 5, n = 1
U(53) = 16.5, p = 0.0001
Braak NFT stage [10] NFT stage 5, n = 3
NFT stage 6, n = 24
NFT stage 0, n = 2 NFT stage 1, n = 3 NFT stage 2, 
n = 11 NFT stage 3, n = 11 NFT stage 4, n = 1
U(53) = 0.500, p = 0.0001
CERAD [43] C, n = 27 Negative, n = 23 A, n = 3 B, n = 2 –
NIA-AA [44] High, n = 27 No, n = 8
Low, n = 18 Intermediate, n = 2
–
Braak LB stage [9] LFB stage 0, n = 25
LFB stage 1, n = 0
LFB stage 2, n = 1
LFB stage 3, n = 1
LFB stage 0, n = 24
LFB stage 1, n = 1
LFB stage 2, n = 1
LFB stage 3, n = 2
–
McKeith criteria [42] No LBD, n = 25
Amygdala predominant, 
n = 2
No LBD, n = 24
Brainstem, n = 2
Amygdala predominant, n = 2
–
VCING criteria [53] Low, n = 28 Low, n = 25
Moderate, n = 2
–
TDP-43 in AD score [30] Stage 0, n = 12
Stage 1, n = 3
Stage 2, n = 4
Stage 3, n = 2
Stage 4, n = 6
Stage 0, n = 21
Stage 1, n = 3
Stage 2, n = 1
Stage 3, n = 1
Stage 4, n = 2
–
CAA score [46] Stage 0, n = 1
Stage 1, n = 3
Stage 2, n = 12
Stage 3, n = 9
Stage 4, n = 3
CapCAA absent, n = 1
CapCAA present, n = 26
Stage 0, n = 15
Stage 1, n = 5
Stage 2, n = 8
CapCAA absent, n = 15
CapCAA present, n = 13
–
MMSE (±SD) [19] 5.82 (5.36) 26 (4.34) t(21) = 8.269, p = 0.0001
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of demyelination) and haematoxylin and eosin (H&E), 
for visualisation of white matter artery/arteriole walls for 
assessment of SVD. Immunohistochemistry was performed 
for chronic axonal transport dysfunctional marker non-
phosphorylated SMI32 (antibody SMI32) [36, 63], as well 
as for HPτ (antibody AT8) and Aβ peptide (antibody 4G8) 
(details on primary antibodies and antigen retrieval proto-
cols for immunohistochemistry are presented in Table 2). 
Immunopositivity was detected using the Menarini X-Cell-
Plus HRP Detection Kit (Menarini Diagnostics, Winnersh-
Wokingham, UK) with 3,3 diaminobenzidine (DAB) as a 
chromagen and haematoxylin as a counter stain. All his-
tologically and immunohistochemically stained sections 
were subsequently dehydrated through a series of alcohols, 
cleared and mounted using DPX (CellPath, Powys, UK).
Image analysis
All image analysis was performed blinded to neuro-
pathological diagnosis. Whole LFB stained sections were 
scanned using an Epson Perfection V700 scanner (dual 
lens system) and monochrome images were uploaded 
into Image-Pro Plus software program (Media Cybernet-
ics Inc, USA; version 6.3). White matter area was manu-
ally delineated from the cortical ribbon using the freehand 
selection tool (Fig. 1a) and total white matter area recorded 
(Fig. 1ai). The WML area was identified based on a defined 
reduction in grey colour that is clearly differentiated from 
the surrounding normal appearing white matter (NAWM) 
with the naked eye, and was confirmed by the ‘bubbly’ 
like appearance and loosening of tissue under microscopic 
examination [54]. To differentiate between the WML 
and NAWM, the 8-bit grey scale threshold was manually 
adjusted to select only the WML area (Fig. 1aii). The per-
centage area of WML per total white matter area was calcu-
lated and expressed as percentage WML area (WMLA) to 
obtain a measure of overall WML severity. The integrated 
optical density (IOD) of the LFB stain was measured. 
The IOD is the amount of light able to transmit through a 
sample and represents a measure of the intensity of histo-
logical staining. In Image Pro Plus a pixel value of 0 rep-
resent black and 255 represents white, therefore, a higher 
value signifies a greater amount of light transmission, i.e. 
a lighter stain, which, regarding LFB staining, indicates 
a reduction of myelin. Three images from the WML and 
three images from the NAWM were randomly captured 
at 200× magnification using a Nikon 90i microscope and 
uploaded on Image-Pro Plus. The mean IOD per pixel was 
recorded for each image and a subsequent mean IOD per 
pixel for WML and NAWM per case were calculated.
On LFB stained sections, the WMLA was identified 
macro- and microscopically and delineated by hand using 
a permanent marker pen to clearly differentiate between Ta
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WML and NAWM. This delineated section was subse-
quently used to identify the corresponding WMLA in 
the adjacent Bielschowsky and SMI32 stained sections 
(Fig. 2a). On both Bielschowsky and SMI32 stained sec-
tions, 3 × 3 single images at 200× magnification were 
captured in WMLA and then combined to yield one large 
image representing an area of 1.7 mm2. This procedure was 
performed five times in each WML and NAWM to give a 
total of ten large images representing an area of 1.7 cm2 
per section (Fig. 2b–bi). Using NIS elements version 3.0 
(Nikon, Surrey, UK), individual and standardized Red 
Green Blue (RGB) thresholds for Bielschowsky’s stain-
ing and SMI32 immunoreactivity (IR) (axonal swellings 
and ovoids (Fig. 2bii)) were applied to the large images 
(Fig. 2biii–biv). If necessary, large images were subjected 
to manual setting of regions of interest to exclude vessels 
and perivascular spaces and artefacts (Fig. 2biii, white 
arrow). For the Bielschowsky’s staining, the RGB thresh-
old was manually adjusted until all visible axons were 
included. For SMI32-IR, RGB intensity values for binary 
layer pixels were set as follows; R14-168, G4-158, B0-53. 
The area covered by Bielschowsky’s stain was measured 
and its percentage of the total measured area calculated 
and expressed as Bielschowsky’s area (BiA). As for Biels-
chowsky’s stain the percentage area covered by SMI32-IR 
was determined, but to adjust for overall axonal density 
SMI32-IR percentage areas were first divided by BiA and 
multiplied by 100 and the resulting values are expressed as 
SMI32-IR. For both BiA and SMI32-IR mean regional val-
ues were calculated for the WMLA and NAWM per case.
For the quantification of cortical protein aggregates, 
four areas of parietal cortical tissue were selected on AT8 
and 4G8 immunostained tissue sections. The four parietal 
cortex sample areas included sulci, midsection and gyri to 
yield an accurate mean measure of cortical pathological 
burden as protein aggregates have been shown to be highest 
in the sulcus and lowest in the gyral tip [20] (Fig. 3a–ai). 
At each cortical location, 3 × 3 single images were cap-
tured at 200× magnification and combined into one large 
image as previously described. If necessary large images 
were subjected to manual setting of regions of interest to 
exclude white matter and meningeal structures. Standard-
ized RGB thresholds were applied separately for AT8 and 
4G8 (Fig. 3aii). RGB intensity values for binary layer pix-
els were set as follows; AT8: R25-170, G27-156, B11-126; 
4G8: R50-180, G20-168, B8-139. In addition, we set a 
size restriction threshold for the assessment of 4G8, which 
excluded the measurement of immunoreactive signals with 
an area below 100 μm2; this was necessary to ensure that 
physiological APP that is stained with 4G8 antibody was 
Fig. 1  a LFB stained sections were scanned and monochrome 
images were uploaded into Image-Pro Plus software program where 
the white matter was manually delineated to create a region of inter-
est (green line). ai Using manual adjustment of the 8-bit grey scale 
threshold, total white matter area measured within the region of inter-
est only. aii Using manual adjustment of the 8-bit grey scale thresh-
old the WML was measured. Percentage area of WML per total white 
matter area was calculated and is expressed in the manuscript as 
WML area (WMLA). Scale bar 1 cm, valid for a–aii
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not included in the measurement. The percentage areas cov-
ered by AT8 and 4G8 immunoreactivity were measured and 
the mean values for the four sample areas were calculated 
and are expressed as AT8-IR and 4G8-IR, respectively.
Sclerotic index (SI) is a surrogate marker of SVD 
severity. SI measurements were performed on H&E 
stained parietal tissue sections. SI was calculated 
using the formula SI = 1 − (internal diameter/external 
Fig. 2  a WML were identified on LFB stained sections of pari-
etal tissue and delineated from the NAWM by hand. This was used 
to identify the same WMLA on serial sections stained with Biels-
chowsky’s silver stain and SMI32. b A SMI32 stained section of 
parietal tissue indicating the five randomly selected areas for image 
capture in both the WMLA (black boxes) and NAWM (red boxes). bi 
3 × 3 large image acquisition of SMI32-IR in WMLA. bii Magni-
fied photomicroimage of SMI32 axonal positive pathology includ-
ing discontinuous lines (white arrow) and end-bulbs axonal spheroid 
(black arrow). biii Image bi with applied bespoke SMI32 threshold 
including an example of artefact removal (white arrow). biv is image 
bii indicating discontinuous lines (white arrow) and end bull axonal 
spheroid (black arrow) with applied SMI32 threshold. Cellular nuclei 
were excluded from assessment (white arrow head). Mean area cov-
ered by IR was stated as a percentage of the total image area and the 
respective values are expressed as SMI32-IR. LFB luxol fast blue, 
Biel Bielschowsky’s silver stain, WMLA white matter lesion area, 
NAWM normal appearing white matter, IR immunoreactivity. Scale 
bar 50 mm, valid for all images in image a and image b; 100 μm, 
valid for bi, biii; 50 μm, valid for bii, biv
Acta Neuropathol 
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diameter); the SI of normal arteries and arterioles ranges 
from 0.2 to 0.3, while an SI of 0.3 to 0.5 indicates mild 
to moderate SVD and SI values >0.5 are seen in severe 
SVD [33]. A maximum of eight randomly selected cer-
ebral white matter arteries and/or arterioles >50 μm 
diameters were identified from the whole white matter 
(Fig. 3b) and a single image captured at 200× magnifi-
cation. SI was calculated on single vessel images using 
the software program VasCalc as previously described 
[66] (Fig. 3bi). Individual SI values were used to calcu-
late a mean SI value for the parietal white matter in each 
case.
Biochemistry
Frozen (−80 °C) coronal slices incorporating the parietal 
lobe were brought to −20 °C in a freezing cabinet and 
sub-dissected to remove Brodmann area 40/22 and its 
adjoining white matter. 10 μm frozen sections were cut 
and fixed in 10% buffered aqueous formaldehyde solu-
tion for 1 h and then histochemically stained with LFB 
as described above. On the slide, the WML was identified 
microscopically and delineated by hand to clearly dif-
ferentiate between WML and NAWM and used to guide 
frozen tissue extraction. Approximately 250 mg of tissue 
Fig. 3  a AT8 stained parietal section indicating the four sample 
areas. ai 3 × 3 large image acquisition of cortex with AT8-IR. aii 
Image ai with applied bespoke threshold for AT8-IR only. Mean area 
covered by IR was stated as a percentage of the total image area and 
the respective values are expressed as AT8-IR. b H&E stained sec-
tion of parietal tissue with deep white matter indicated (dashed line). 
Microphotoimages of up to eight individual white matter vessels were 
captured from the white matter for SI assessment. bi A microphoto-
image of a white matter arteriole. SI was calculated using VasCalc 
software; [66] the internal and external diameters were measured 
three times to yield a SI value a mean SI value was calculated per 
section. IR immunoreactivity, SI sclerotic index, Dext external diam-
eter, Dint internal diameter. Scale bar 1 cm, valid for images in a, b; 
100 μm, valid for ai, aii; 50 μm, valid for bi
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was removed from each WML and the NAWM. Lysis 
buffer containing 0.2 M tetraethyl ammonium bicarbo-
nate, pH 7.2 (TEAB; Sigma, UK) and protease inhibitor 
tablets (1 tablet per 10 ml; Complete, Roche, Burgess 
Hill, UK) were added to tissue samples at a 1 mg/1 ml 
ratio. Samples were then homogenised using an Ultra-
turrax T10 homogeniser (S10N-5G 5 mm diameter probe; 
30,000 rpm), aliquoted at 500 μl with 5 μl of 1% SDS 
and stored at −80 °C until required.
Total protein concentration was determined by Bradford 
assay and final protein concentration for all samples was 
adjusted to 3 mg/ml. Using commercially available sand-
wich enzyme-linked immunosorbent assays (ELISA) kits, 
five proteins were measured in both WML and NAWM tissue 
samples, including Wallerian degeneration markers calpain2 
(CAPN2; large catalytic subunit (80 kDa) found in myeli-
nated axons), calpain specific inhibitor calpastatin (CASP) 
[21], calpain specific spectrin breakdown product 145 
(SBDP145) [68], and ischemia markers myelin-associated 
glycoprotein (MAG; myelin sheath protein, expressed only 
in the myelin loops and highly vulnerable under ischemic 
conditions) and proteolipid protein (PLP; myelin sheath pro-
tein that is abundant throughout the sheath and stable under 
ischemic conditions) [6] to calculate the MAG:PLP as an 
indication of pre-mortem white matter ischemia [6]. Details 
regarding ELISA kits are presented in Table 3. ELISA pro-
tocols were followed according to manufactures instructions. 
Briefly, working standards and samples were prepared/diluted 
as required. 100 μl of standard and sample were pipetted into 
wells of the 96-well coated microplates and incubated for 2 h 
at 37 °C. Liquid was removed and 100 μl of biotin-antibody 
was applied to each well and incubated for 1 h at 37 °C. Wells 
were then aspirated and washed three times with wash buffer 
before 100 μl HRP-avidin solution was applied to each well 
and incubated for 1 h at 37 °C. Wells were aspirated and 
washed a further five times and 90 μl of TMB substrate was 
applied to each well and incubated for 30 min at 37 °C. The 
reaction was stopped with 50 μl of stop solution per well and 
absorbance was read at appropriate wavelength within 5 min 
in a FLUOstar Omega multi-detection microplate reader 
(BMG Labtech, Aylesbury, UK).
Statistics
The Statistical Package for Social Sciences software 
(SPSS ver. 21) was used for statistical evaluation. Vari-
ables were tested for normality using the Shapiro–Wilk 
test and visual inspection of variable histograms. Dif-
ferences in related variables (WML vs. NAWM) were 
assessed using non-parametric Wilcoxon test. Group 
effects were assessed using either non-parametric 
(Mann–Whitney U) or parametric (independent samples 
t test) procedures. Where appropriate, Spearman’s (ρ) 
and Pearson’s (r) correlation coefficients were used to 
assess associations between variables. Exploratory step-
wise linear regression analyses were also conducted to 
investigate pathological predictors of WMLA and WML 
pathology.
Results
No significant differences were observed in age or post-
mortem delay between AD and control groups. AD cases 
had significantly higher levels of AD neuropathological 
change and significantly lower MMSE scores compared to 
controls (Table 1). Fifty cases contained at least one WML 
and all 55 cases underwent NAWM assessment.
Histological characteristics of WML and NAWM
Mean values for WMLA, BiA, LFB-IOD and SMI32-IR 
for both WML and NAWM are presented in supplemen-
tary Table 1. Briefly, with regards to the whole cohort, 
when compared to NAWM tissue, WML tissue had sig-
nificantly lower BiA (p < 0.0001), indicating axonal loss, 
significantly higher LFB-IOD values (p < 0.0001), indicat-
ing demyelination, as well as significantly higher SMI32-
IR (p < 0.01), indicating increased chronic axonal trans-
port dysfunction. WMLA was significantly greater in AD 
compared to controls (p < 0.05), but SI values did not differ 
between these groups.
Table 3  Details of ELISA kits used for detection of proteins in frozen tissue samples
Protein ELISA Kit Sample dilution Standard curve (ng/ml) OD wavelength
Cat # Description
CAPN2 CSB-E17822h Human CAPN2 ELISA kit, Cusabio Neat samples 2.5–0.039 450 and 540 nm
CAST CSB-E17483 h Human CAST ELISA kit, Cusabio 1:50 100–1.56 450 and 540 nm
SBDP145 CSB-EQ028022HU Human SBDP145 ELISA kit Cusabio Neat samples 40–0.625 450 and 540 nm
MAG CSB-E17901h Human MAG ELISA Kit, Cusabio Neat samples 20–0.1 450 and 540 nm
PLP MBS266920 Human PLP ELISA Kit, MyBioSource Neat samples 10–0.156 450 nm
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Associations between WML severity and axonal loss, 
demyelination and axonal transport
We examined the relationship between WMLA and BiA, 
LFB-IOD, and SMI32-IR of both WML and NAWM. In 
AD cases, WMLA negatively correlated with both WML-
BiA (ρ = −0.648, p = 0.0001; Fig. 4ai) and NAWM-
BiA (ρ = −0.334, p = 0.044; Fig. 4aii). In contrast, no 
correlations were observed in control cases (WML-BiA, 
p = 0.436; NAWM-BiA, p = 0.365; Fig. 4ai–ii), indicat-
ing that increasing WML severity was significantly associ-
ated with axonal loss in the WML and surrounding NAWM 
in AD cases but not in controls. In both AD and controls, 
WMLA correlated with both WML-LFB-IOD (AD, 
ρ = 0.755, p = 0.0001; controls, ρ = 0.413, p = 0.016; 
Fig. 4bi) and NAWM-LFB-IOD (AD, ρ = 0.445, p = 0.01; 
ρ = 0.407, p = 0.018; Fig. 4bii), indicating increasing 
WML severity was associated with demyelination in the 
WML and surrounding NAWM in both AD and control 
cases. Negative correlations were observed between BiA 
and LFB-IOD in both WML (ρ = −0.528, p = 0.004) and 
NAWM (ρ = −0.430, p = 0.013) in AD cases only (con-
trols: WML, p = 0.133; NAWM, p = 0.073) (Fig. 4ci–ii). 
This indicates that in AD cases loss of myelin is primar-
ily due to loss of myelinated axons, unlike control cases 
that exhibited no such association. No correlations were 
revealed between WML-SMI32-IR or NAWM-SMI32-
IR and WMLA in either AD (WML, p = 0.390; NAWM, 
p = 0.186) or control cases (WML, p = 0.091; NAWM, 
p = 0.402). To investigate whether WML-BiA or WML-
LFB-IOD independently predicted WMLA, stepwise linear 
regression analysis was performed. In the AD group both 
WML-BiA (β = −0.375, p = 0.013) and WML-LFB-IOD 
(β = 0.761, p = 0.0001) significantly predicted WMLA 
(model R2 = 0.688, F(2) = 23.18, p < 0.001). In contrast for 
controls, only WML-LFB-IOD was found to be a signifi-
cant predictor of WMLA (model R2 = 0.332, F(2) = 12.41, 
p < 0.01; β = 0.601, p = 0.002) and not WML-BiA 
(p = 0.957).
Influence of cortical neurodegenerative pathology, SVD 
and CAA on WML severity, axonal loss, demyelination 
and axonal transport
We investigated whether cortical neurodegenerative AD-
pathologies and SVD were associated with white matter 
pathological changes. A correlation matrix for the whole 
cohort, as well as separately for AD and controls, is pre-
sented in supplementary Table 2. No correlations were 
seen when statistical analysis was performed separately 
for AD and controls. However, with regards to the whole 
cohort, which is inclusive of Braak stage 0–VI and Thal Aβ 
Phases 1–5, WMLA correlated with AT8-IR (ρ = 0.284, 
p = 0.022) but not 4G8-IR (p = 0.072), SI (p = 0.451) 
or CAA (p = 0.185). WML-LFB-IOD was also corre-
lated with AT8-IR (ρ = 0.289, p = 0.002) but not 4G8-IR 
(p = 0.147), SVD (p = 0.433) or CAA (p = 0.492). No 
correlations were observed between WML-BiA and any 
neurodegenerative pathology, SI or CAA. Finally, we cor-
related WML-SMI32-IR with AT8-IR, 4G8-IR, SI and 
CAA to determine if AD-associated pathologies or SVD 
was involved in chronic axonal transport dysfunction; 
however, no significant correlations were yielded with any 
pathology (AT8, p = 0.274; 4G8, p = 0.153; SI, p = 0.314; 
CAA, p = 0.916).
Wallerian degeneration and ischemia
Firstly, we investigated the regulation and activation of 
the protease calpain2; calpain2 was increased in the WML 
compared to NAWM (p = 0.073) and calpastatin (calpain2 
inhibitor) levels were decreased in the WML compared to 
NAWM (p = 0.10) indicating corresponding down regu-
lation of calpastatin and up regulation of calpain2. A cor-
relation between mean values of calpain2 and SBDP145 
(ρ = 0.521, p = 0.0001) was observed, indicating specific 
calpain2 activity.
Calpain2 was significantly higher in both the WML 
(p = 0.022) and NAWM tissue (p = 0.005) of AD cases 
compared to controls (Fig. 5a). No significant differ-
ence was revealed with WML- or NAWM MAG values 
between AD and control cases (WML, p = 0.457; NAWM, 
p = 0.460; Fig. 5b), in contrast to WML- and NAWM PLP 
that was found to be significantly reduced in AD cases 
(WML, p = 0.0001; NAWM, p = 0.007; Fig. 5c). The 
MAG:PLP was significantly lower in WML tissue of con-
trol cases compared to AD cases (p = 0.02; Fig. 5d), how-
ever, no significant differences was seen in NAWM tissue 
between AD and controls (p = 0.221).
With regards to the whole cohort that is inclusive 
of Braak NFT stage 0–VI and Thal Aβ Phases 1–5, we 
examined correlations of WML measures of calpain2, 
MAG, PLP and MAG:PLP with pathological meas-
ures of cortical neurodegenerative AD-pathologies, SVD 
and CAA to investigate the pathological relationships 
of white matter changes. Calpain2 correlated with AT8-
IR (ρ = 0.369, p = 0.01) and 4G8-IR (p = 0.012), but 
not SI (p = 0.184) or CAA (p = 0.433). No correlations 
were seen between MAG values and AT8-IR (p = 0.163), 
4G8-IR (p = 0.256), SI (p = 0.210) or CAA (p = 0.590). 
PLP negatively correlated with both AT8-IR (ρ = −0.488, 
p = 0.001) and 4G8-IR (ρ = −0.401, p = 0.004), but not 
with SI (p = 0.273) or CAA (p = 0.536). MAG:PLP cor-
related with both AT8-IR (ρ = 0.347, p = 0.028) but not 
4G8-IR (p = 0.076), SI (p = 0.705) or CAA (p = 0.453). 
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Fig. 4  Scatter graphs show; ai negative correlations between WMLA 
and WML-BiA in AD cases only. aii Negative correlations between 
WMLA and NAWM-BiA in AD cases only. bi A positive correlation 
between WMLA and WML- and bii NAWM- LFB-IOD was seen in 
both AD and control cases. ci a negative correlation between WML-
BiA and WML-LFB-IOD in AD cases only. cii A negative correlation 
between NAWM-BiA and NAWM-LFB-IOD was seen in AD cases 
only. p values and associated correlation coefficients are shown in 
main text. WML white matter lesion, NAWM normal appearing white 
matter, WMLA white matter lesion area, BiA Bielschowsky’s area, 
LFB-IOD luxol fast blue integrated optical density
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No correlations were seen when statistical analysis was 
performed separately for AD and controls.
Discussion
Here, for the first time, we reveal differences in the under-
lying pathology and molecular signatures of parietal WML 
between AD and non-demented elderly that indicate dif-
fering aetiologies. Pathologically, increasing severity of 
WML in AD is associated with both axonal loss and demy-
elination, in contrast to non-demented individuals in which 
WML are associated with demyelination only. Biochemi-
cal analysis indicated an increase in calpain2 levels in the 
white matter of AD cases, which is suggestive of increased 
Wallerian degeneration that is associated with increasing 
cortical burden of AD-related pathologies but not with 
SVD. Furthermore, MAG:PLP values were reduced in the 
WML tissue of control cases, indicating hypoperfusion. 
Overall, our data indicate that parietal WML (WMH) seen 
in AD are associated with demyelination and axonal loss 
as a result of degenerative axonal loss and not ischemic 
damage as seen in normally aged controls.
The pathogenesis of WML is often being assumed to be 
the result of SVD; hence, the detection of in vivo WMH 
frequently supports the diagnosis of VCI/VaD. However, 
ample evidence has indicated that WML in AD may well 
be the result of degenerative axonal loss due to Wallerian 
degeneration triggered by cortical AD pathology. Indeed, 
we found that WML were significantly more severe in the 
AD cases compared to the non-demented cases, in agree-
ment with findings in previous studies [8, 40, 49]. Our 
thorough, quantitative neuropathological investigations 
revealed that in AD axonal loss and demyelination, in 
both the WML itself and the surrounding NAWM, were 
associated with and are a predictor of increasing severity 
of WML. This is in contrast to non-demented cases where 
only demyelination predicts and associates with WML 
Fig. 5  Box plots show; a Calpain2 was significantly higher in the 
WML tissue of AD cases compared to controls. b No significant 
difference was seen in WML-MAG between AD and control cases. 
c PLP was significantly lower in the WML tissue of AD cases com-
pared to controls. d MAG:PLP was significantly lower in the WML 
tissue of control compared to AD cases. *p < 0.05; ***p < 0.001. 
Exact p values are shown in main text. AD Alzheimer’s disease, MAG 
myelin associated glycoprotein, PLP proteolipid protein
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severity. These pathological changes were further sup-
ported by our biochemical analysis of WML tissue, which 
showed a significant decrease in PLP levels in AD, indica-
tive of  axonal atrophy, as well as equal loss of MAG levels 
between AD and control brains, signifying demyelination 
in both groups. Both the pathological and biochemical data 
indicate that increased myelin loss in the AD group is likely 
due to severe axonal atrophy. A previous neuropathological 
study investigated differences in myelin and axonal densi-
ties of WML between AD and controls cases and found no 
differences; however, this was based on WML from any 
brain region and was not specific to the posterior or medial 
temporal regions [23]. We can, therefore, report for the first 
time differences in the pathological composition WML 
between AD cases and controls in the parietal white matter.
Degenerative axonal loss in AD can occur as a conse-
quence of Wallerian degeneration [15, 29, 65] where cal-
pain is the primary protease involved in axonal destruction 
[38]. Our data revealed that calpain levels were signifi-
cantly increased in WML in AD compared to controls and 
were associated with increasing cortical HPτ and Aβ 
pathology burden but not with SVD. Calpain activation 
is thought to be triggered by anterograde axonal transport 
disruption and/or blockage [12, 39], which are a common 
early feature in AD. Axonal SMI32 pathology, which is 
an indicator of chronic axonal transport dysfunction [48], 
was found to be significantly higher in WML compared 
to NAWM indicating disruption of axonal transport in 
the WML area. However, no difference in the amount of 
SMI32 pathology was found between AD and controls, and 
therefore, we cannot conclude whether axonal transport 
dysfunction is the instigator of increased levels of calpain 
in the AD group.
WML in the control cases, that primarily consisted of 
demyelination, were found to be the result of ischemia 
as indicated by a significant reduction in the MAG:PLP 
ratio. Barker and colleagues had previously measured the 
MAG:PLP ratio in the parietal white matter of AD and 
control cases and found no respective differences. How-
ever, they did not distinguish specifically between NAWM 
and WML [6], hence the data from Barker and colleagues 
is in agreement with our findings in the NAWM. Only in 
the WML tissue of control cases was the MAG:PLP ratio 
significantly lower compared to WML seen in AD cases 
indicating that in AD WML were not primarily associated 
with hypoxia. Ischemia has long been associated as the pri-
mary cause of WML and WMH in both normal ageing and 
dementia [24, 45, 47]; however, with the addition of more 
sensitive and reliable biochemical measures of ischemic 
change [6] we could now clarify that ischemia is not the 
only potential cause for WML and it appears unlikely to be 
the major cause for posterior WML in AD. Naturally, SVD 
in AD cases may have an influence on the development of 
WML; however, our data indicates that the respective influ-
ence of HPτ pathology exceeds that of SVD.
Cortical HPτ pathology was associated with both WML 
severity and demyelination, while the latter were not associ-
ated with arteriopathy in cases showing considerable corti-
cal HPτ. While no direct pathological associations between 
HPτ or Aβ pathology burden with decreased axonal den-
sity were revealed, a decrease in WML PLP levels (indica-
tive of axonal atrophy) was associated with increasing HPτ 
pathology. One may speculate that the increasing burden of 
cortical HPτ pathology is a trigger of Wallerian degenera-
tion. Indeed, cortical HPτ has been implicated as an insti-
gator of degenerative axonal loss in AD. Previous quantita-
tive neuropathological [40], longitudinal community-based 
[52] and biomarker studies [60] have indicated an associ-
ation between HPτ and the development of WMH in the 
absence of SVD [17, 35, 60]. Moreover, in Pick’s disease, 
which is a primary tauopathy, white matter degeneration 
and demyelination was significantly more severe in white 
matter regions proximal to severe cortical HPτ pathology 
[58]. However, the exact underlying mechanisms of HPτ-
associated axonal degeneration are still unclear and further 
mechanistic investigations are warranted.
It is important to note that our study focused specifically 
on WML located in the parietal region. Studies have indi-
cated that in non-demented patients WML/WMH are more 
prevalent in the frontal region compared to patients with 
AD [61, 64] and are attributed to cerebrovascular disease 
[61, 62]. The difference in aetiology could be attributed to 
the posterior and MTL regions being affected early with 
HPτ pathology deposition [10]. Differentiation of the aeti-
ology and pathological/biochemical signatures of WML/
WMH from the anterior and posterior regions of the brain 
is warranted for diagnostic clarification.
CAA was not associated with any measure of WML 
pathology or molecular measure of Wallerian degenera-
tion or ischemia in agreement with a previous neuropatho-
logical and imaging study [56]. Due to the high prevalence 
of CAA in AD statistical associations between CAA and 
WML may possibly be caused by the presence of concomi-
tant cortical AD pathology, specifically HPτ pathology.
Understanding the underlying mechanisms of WML/
WMH pathogenesis is crucial for the accurate diagno-
sis and therapeutic interventions of patients with cogni-
tive impairment, in particular, as current clinical criteria 
for VaD/VCI [22] and mixed AD/VaD [16] are based 
on the detection of WMH as surrogate marker for SVD. 
Our findings provide further evidence that the underly-
ing aetiology of WML in AD is not restricted to SVD 
and may indeed be indicative for AD pathology. If WML 
are invariably used as a surrogate biomarker for SVD, 
as suggested by current clinical guidelines [16, 22], this 
will bias cohort stratification in clinical trials, result in 
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misdiagnosis of patients, and have a detrimental impact 
on the choice of therapeutic interventions, e.g. AD 
patients being misdiagnosed with VaD would not receive 
acetylcholinesterase inhibitors as recommended for man-
aging mild to moderate AD [18]. As mentioned previ-
ously, our study focused on parietal WML and prior work 
suggests that the aetiology of WML differs by anatomi-
cal location [34], hence, further imaging studies that also 
involve new in vivo imaging of HPτ [11] and Aβ [32] 
pathology and integrate anatomical location, pathophysi-
ology and impact on cognition are warranted. Finally, our 
results call for more detailed neuropathological evalua-
tion of cerebral white matter injury in dementia. Current 
approaches do not adequately assess this important tissue 
and understanding the pathophysiology of white mat-
ter damage is not only important to clinical phenotype, 
but may open avenues to new therapeutics to modify the 
course of degenerative dementias.
In conclusion, the pathological and biochemical sig-
natures of parietal WML/WMH differ between AD and 
non-demented individuals, and in AD the pathogenesis 
of posterior WML/WMH is associated with degenerative 
axonal changes probably occurring secondary to corti-
cal AD-pathology. These novel findings support previous 
neuroimaging studies that indicate Wallerian degenera-
tion-associated axonal damage may be a cause of poste-
rior WMH in AD. Further elucidation of the role of AD 
pathologies in the pathogenesis of WML/WMH is para-
mount for accurate diagnosis and improved stratification 
of patients for clinical trials.
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